Botox versus Dysport versus Xeomin versus Daxxify: what actually differs

Botox, Dysport, Xeomin, and Daxxify are separate botulinum toxin type A prescription products. They differ in formulation, labeled indications, dosing studies, storage and preparation details. Their potency units are product-specific and cannot be converted by a universal ratio.

The four names are often treated as interchangeable shorthand for wrinkle injections. Their FDA labels make the opposite point: each product has its own manufacturing process, formulation, potency assay, dose, injection pattern, indications, and clinical studies. A useful comparison therefore starts with the proposed facial area and the exact vial—not a promised number of “Botox-equivalent” units. ¹²³⁴

Four products, four dosing systems

All four temporarily reduce activity in injected muscles by acting at the neuromuscular junction. FDA approval belongs to each named product and indication, not to the category word “Botox.” The table deliberately shows the cosmetic indications that drive most med-spa comparisons; several full labels also contain different therapeutic indications and doses that should not be imported into an aesthetic quote.

The ingredient names identify different preparations: onabotulinumtoxinA in Botox, abobotulinumtoxinA in Dysport, incobotulinumtoxinA in Xeomin, and daxibotulinumtoxinA-lanm in Daxxify. The excipient systems differ too. Those details are not trivia when a clinic changes brands, because the label for each product explicitly says its potency units cannot be converted into the units of another botulinum toxin product.

That makes “price per unit” an incomplete comparison. A larger numeral on a Dysport quote does not by itself mean a larger biological dose than a smaller Botox numeral, and a clinic should not apply a universal conversion ratio as though it were printed in the labels. Compare the total proposed treatment, placement map, product identity, and follow-up—not the unit count in isolation.

Labeled uses are product-and-area specific

The cited labels are not head-to-head comparisons, and their study designs differ. A first perceptible change is not the same endpoint as a Day 30 or Week 4 responder assessment, return to a severity grade, or chosen retreatment date. Duration claims must name the product, dose, area, endpoint, and study; a category average is not a guarantee.

Botox Cosmetic, Dysport, Xeomin, and Daxxify do not carry identical cosmetic indication lists. A product may be approved for one pattern of facial lines while another area discussed in a consultation is off-label. Even within a labeled indication, the studied dose and injection sites belong to that named product. “Botulinum toxin is FDA approved” does not establish that every brand, area, age group, or placement proposal matches labeling.

Labels are the cleanest source for what regulators evaluated, but they are not head-to-head scorecards. Studies can use different wrinkle scales, responder definitions, photo conditions, visit schedules, doses, and analysis populations. A result at maximum frown is not the same endpoint as a result at rest; investigator ratings and patient assessments can also produce different response percentages. Cross-trial percentages should not be ranked without accounting for those design differences.

Onset and duration need the same product-level discipline. The four labels do not supply one standardized onset race. People may notice reduced contraction before a label’s primary assessment visit, while Daxxify’s glabellar studies followed subjects well beyond Week 4; neither fact proves the same timing for every person, dose, facial area, or competing product. Ask what “starts working” and “lasts” mean: first perceptible change, peak result, return to a specified severity score, or the date someone chooses retreatment.

Formulation differences do not create an automatic winner

Xeomin is often described as a preparation without accessory complexing proteins, while Daxxify uses a peptide-containing formulation. Botox and Dysport have their own protein and excipient profiles. Those facts identify formulations; they do not prove that one will look more natural, spread in a universally predictable way, resist antibodies, or work best for a particular face. A comparative claim should point to evidence for the actual indication and protocol, not infer superiority from an ingredient list.

Preparation and handling also shape the real-world plan. The clinician should follow the current label for storage, reconstitution where required, concentration, and administration. Dilution changes concentration and injection volume; it does not change how many product-specific units were drawn. If a provider uses a nonstandard concentration or an off-label area, that choice should be explained separately from the product’s approved identity.

Material risks and response planning

Each label carries a boxed warning about distant spread of toxin effect. Swallowing, speaking, or breathing difficulty and generalized weakness require urgent attention. Consultation should also cover anatomy, baseline eyelid or brow position, prior toxin exposure, medications, and the plan for functional change.

Local outcomes depend on anatomy and placement: eyelid or brow droop, asymmetry, an altered smile, dry eye, headache, injection-site effects, or unwanted weakness can matter even when no systemic problem occurs. Baseline brow position, eyelid function, facial asymmetry, prior facial surgery, neuromuscular conditions, infection at a proposed site, pregnancy or breastfeeding questions, and relevant medicines belong in the intake described by the applicable label.

The boxed warning is not a prediction that a routine cosmetic treatment will cause distant spread, but it is a reason to know the urgent response. New swallowing, speaking, or breathing difficulty, generalized weakness, or other concerning symptoms after treatment warrant prompt medical attention. The clinic should state who assesses a functional problem, how after-hours contact works, and when emergency services are the correct route.

Before injection, the record should name the manufacturer, product, lot, expiration, reconstitution details, total units, units by site, and injector. That is especially important for future comparisons: “I received 40 units” is not interpretable without the brand and placement.

Questions that make four quotes comparable

1. 1. Which exact product and lot will be recorded? The answer should appear in the treatment record, not only on a menu or verbal estimate.
2. 2. Is this facial area on that product's current label? If it is off-label, ask what evidence and anatomical reasoning support the proposed use.
3. 3. How were these product-specific units selected? Request units by muscle or region; reject a conversion explained only as a fixed brand ratio.
4. 4. What dates define onset, peak assessment, and duration? Agree on the expression, lighting, rating method, and visit window before comparing photographs.
5. 5. What function is intentionally preserved? Discuss brow position, smile, eyelid closure, speech, or chewing when the placement could affect them.
6. 6. What happens if the result is uneven or too strong? Clarify observation time, review access, and escalation before assuming that adding more toxin is the answer.

Choose the plan, not the brand story

Compare the exact product, labeled versus off-label area, proposed product-specific units, placement map, review timing, and what success means. A low price per unit is not comparable when the units themselves are not interchangeable.

A sound choice can favor any of the four products when the clinician can connect that product’s label and evidence to the requested area, explain the dose without pretending the units are interchangeable, and describe how movement will be assessed. Familiarity with a formulation and consistent documentation may be more useful than a claim that one toxin is categorically softer, stronger, faster, or longer lasting.

Build maintenance into the comparison without prescheduling an endless sequence. Decide what degree of movement reduction is enough, when the first result will be judged, and whether retreatment is based on a return of the original finding rather than a calendar membership. Changing brands at a later visit should trigger a fresh product-and-unit discussion.

The bottom line is exactness: the named vial, the labeled or off-label area, product-specific units, a muscle-level placement plan, defined photo conditions, and a response route. Those six details turn four familiar brand names into a comparison that can actually be evaluated.